Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab.

Murtuza Bharmal, Sandra Nolte, Céleste Lebbé, Laurent Mortier, Andrew S. Brohl, Nicola Fazio, Jean-Jacquez Grob, Sara Pusceddu, Glenn J. Hanna, Jessica C. Hassel, Felix Kiecker, Barbara Ellers-Lenz, Marcis Bajars, Gülseren Güzel, Paul Nghiem, Matthias Hunger, Michael Schlichting, Mickaël Henry-Szatkowski, Sandra P. D'Angelo

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: To evaluate changes in health-related quality of life (HRQoL) in a Phase II trial (NCT02155647) of treatment-naive patients with metastatic Merkel cell carcinoma treated with avelumab (15-month follow-up). Materials methods: Mixed-effect Models for Repeated Measures were applied to HRQoL data (FACT-M; EQ-5D-5L) to assess changes over time. Clinically derived progression-free survival was compared with HRQoL deterioration-free survival. Results: Overall, we saw relative stability in HRQoL among 116 included patients, with nonprogression associated with statistically and clinically meaningful better HRQoL compared with progressive disease. Deterioration-free survival rates (49-72 months, 40-582 months) were consistently higher/better compared with progression-free survival rates (41/31/12 months). Conclusion: These findings show unique longitudinal HRQoL data for treatment-naive metastatic Merkel cell carcinoma patients treated with avelumab. Clinical trial registration: NCT02155647 (ClinicalTrials.gov).
Original languageEnglish
JournalFuture Oncology
Issue number27
Publication statusPublished - Sep 1 2020

Fingerprint Dive into the research topics of 'Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab.'. Together they form a unique fingerprint.

Cite this